P/E ratio for Charles River Laboratories (CRL)
P/E ratio as of May 2024 (TTM): 23.4
According to Charles River Laboratories 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 23.3519. At the end of 2022 the company had a P/E ratio of 22.8.
P/E ratio history for Charles River Laboratories from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 22.8 | -53.05% |
| 2021 | 48.5 | 42.45% |
| 2020 | 34.0 | 15.21% |
| 2019 | 29.5 | 22.7% |
| 2018 | 24.1 | -43.02% |
| 2017 | 42.3 | 83.03% |
| 2016 | 23.1 | -7.81% |
| 2015 | 25.0 | 6.64% |
| 2014 | 23.5 | -4.37% |
| 2013 | 24.6 | 33.03% |
| 2012 | 18.5 | 45.21% |
| 2011 | 12.7 | -293.14% |
| 2010 | -6.58 | -134.38% |
| 2009 | 19.1 | -666.96% |
| 2008 | -3.38 | -111.85% |
| 2007 | 28.5 | -34.14% |
| 2006 | 43.3 | 108.24% |
| 2005 | 20.8 | -18.29% |
| 2004 | 25.4 | 30.32% |
| 2003 | 19.5 | -43.23% |
| 2002 | 34.4 | -12.77% |
| 2001 | 39.4 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Thermo Fisher Scientific TMO | 38.8 | 66.18% | 🇺🇸 USA |
 SCYNEXIS SCYX | 2.95 | -87.38% | 🇺🇸 USA |
 Repligen
RGEN | 82.3 | 252.30% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.